Down Syndrome Metabolic Health Study

Down Syndrome Clinical Trial

Official title:

Cardiometabolic Risk and Obesity in Adolescents With Down Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01821300
• Other study ID #: 12-009233
• Secondary ID: 1R01HD071981-01A
• Status: Completed
• Start date: February 2013
• Est. completion date: August 25, 2017

Study information

• Verified date: July 2019
• Source: Children's Hospital of Philadelphia
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to determine which measures best capture cardiovascular disease (CVD) risk and type 2 diabetes (T2DM) risk in children and adolescents with Down syndrome (DS).

We hypothesize that DS is associated with worse cardiometabolic risk factors for a given body mass index compared to controls. This difference arises at least in part, from increased fat tissue.

Description:

DS affects 1 per 800 births and is one of the most common causes of developmental disability in the US. Life expectancy for Down syndrome has increased significantly: estimated median survival in the US in 1997 was 49 years. DS is associated with an increased risk for obesity, with an estimated prevalence of 47-48% in adults and 30-50% in children with DS. Adolescents with DS are more likely to have increased adiposity compared to unaffected peers and may be at increased risk for obesity-related co-morbidities, such as type 2 diabetes and cardiovascular disease. How one defines obesity in DS is not clear. Individuals with DS have short stature and possibly increased adiposity, and the body mass index (BMI) used to define obesity for otherwise healthy populations may not accurately depict body fatness or capture cardiometabolic risk in DS.

Congenital heart disease (CHD) affects approximately 50% of individuals with DS; the National Institutes of Health Heart Lung and Blood Institute (NHLBI) Working Group on Obesity and Other Cardiovascular Risk Factors in Congenital Heart Disease highlighted the high prevalence of obesity in the setting of CHD, and called for studies to identify obesity measures that are more sensitive than BMI as well as studies of CVD risk prevention. Unfortunately, clinicians caring for obese adolescents with DS with or without CHD have little scientific evidence upon which to base guidance regarding cardiometabolic risk (CMR): data regarding CVD risk and prevalence of pre-diabetes and T2DM in obese adolescents with DS are lacking.

The measure of body fatness which best predicts CMR in DS is not known. We plan to compare BMI and other measures of body fatness in healthy controls and adolescents with DS to determine which measures best capture CVD and/or T2DM risk. These data will equip medical providers with the tools to better assess risk, initiate prevention measures, and guide screening in adolescents with DS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 257
• Est. completion date: August 25, 2017
• Est. primary completion date: August 25, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 20 Years

Eligibility

Inclusion Criteria:

• Both groups: Ages 10 - 20

• Both groups: Parental/guardian permission (informed consent) and if appropriate, child assent.

• Down syndrome group only: diagnosis of Down syndrome

Exclusion Criteria (both groups):

• Major organ system illness (such as leukemia), except for type 2 Diabetes

• Cyanotic congenital heart disease and/or pulmonary hypertension

• Medically unstable congenital heart disease

• Pregnancy

• Genetic syndrome known to affect glucose tolerance

• Familial hypercholesterolemia

• Currently treated with medications known to affect insulin sensitivity (other than diabetes agents in participants with type 2 diabetes)

Related Conditions & MeSH terms

• Down Syndrome
• Syndrome
• Trisomy 21

Locations

Country	Name	City	State
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (3)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-HDL Cholesterol	Non-HDL cholesterol measured via fasting blood draw	Study Visit 1
Primary	Lipid Subparticles	Lipoprotein subclass particle analysis run on samples from fasting blood drawn Study Visit 1.	Study Visit 1
Primary	Lipid Subparticles (Size)	Lipoprotein subclass particle analysis run on samples from fasting blood drawn Study Visit 1.	Study Visit 1
Primary	Insulin Resistance	Insulin Resistance (HOMA-IR) was calculated as [fasting insulin (uIU/mL) x fasting glycemia (mmol/L)]/22.5	Study Visit 1
Primary	Cardiometabolic Risk Biomarker Proteins	hs-CRP, PAI-1, and IL-6 run on samples from fasting blood drawn Study Visit 1.	Study Visit 1
Primary	Abnormal Glucose Tolerance	Impaired fasting glucose (IFG) was defined as fasting glucose = 100 mg/dl. Impaired glucose tolerance (IGT) was defined as 2-hour glucose 140-199 mg/dl measured as part of an oral glucose tolerance test.	Study Visit 1
Primary	Visceral Fat	Adiposity measured by Dual-energy X-ray absorptiometry	Study Visit 1
Primary	Body Mass Measures	Adiposity measured by Dual-energy X-ray absorptiometry	Study Visit 1
Primary	Left Ventricular Mass	Cardiac end organ injury assessed by echocardiography. Left Ventricular Mass (LVM) was measured by area/length method using the apical four-chamber and parasternal short-axis views. LVM was calculated as LV area × LV length × 1.05 × 5/6.	Study Visit 1
Primary	Pulse Wave Velocity	Cardiac end organ injury assessed by Pulse Wave Velocity (PWV)	Study Visit 1
Secondary	Health Related Quality of Life - PedsQL	Caregiver-perception of his/her child's health-related QOL was assessed with the use of the parent-proxy report of the Pediatric Quality of Life Inventory (PedsQL) Version 4.0. Sub-scale scores are converted to a 0-100 scale so that greater scores indicate better QOL. Scale scores are computed as the sum of the items divided by the number of items answered (this accounts for missing data). If more than 50% of the items in the scale are missing, the scale score is not computed. The Physical Health Summary Score (8 items) is the same as the Physical Functioning Scale. To create the Psychosocial Health Summary Score (15 items), the mean is computed as the sum of the items divided by the number of items answered in the Emotional, Social, and School Functioning Scales.	Study Visit 1
Secondary	Health Related Quality of Life - IWQOL	Parent perception of the effects of weight on his/her child's QOL was assessed with a caregiver-proxy version of the Impact of Weight on Quality of Life - Kids (IWQOL-Kids) questionnaire. The IWQOL-Kids is a validated, 27-item, self-report measure of weight-related QOL for youth ages 11-19 years. It yields 4 subscales (Physical Comfort, Body Esteem, Social Life, and Family Relations) and a Total score, which have strong psychometric properties, discriminate among weight status groups, and are responsive to weight change. Scaled scores are standardized and range from 0 to 100, with greater scores representing better weight-related QOL.	Study Visit 1

External Links

•   Down Syndrome Metabolic Health Study website